A single-dose of intranasal vaccination with a live-attenuated SARS-CoV-2 vaccine candidate promotes protective mucosal and systemic immunity
An attenuated SARS-CoV-2 virus with modified viral transcriptional regulatory sequences and deletion of open-reading frames 3, 6, 7 and 8 (∆3678) was previously reported to protect hamsters from SARS-CoV-2 infection and transmission. Here we report that a single-dose intranasal vaccination of ∆3678 protects K18-hACE2 mice from wild-type or variant SARS-CoV-2 challenge. Compared with wild-type virus infection, the ∆3678 vaccination induces equivalent or higher levels of lung and systemic T cell, B cell, IgA, and IgG responses. The results suggest ∆3678 as an attractive mucosal vaccine candidate to boost pulmonary immunity against SARS-CoV-2.
| Errataetall: |
UpdateIn: NPJ Vaccines. 2023 Oct 20;8(1):160. - PMID 37863935 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
bioRxiv : the preprint server for biology - (2023) vom: 18. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Adam, Awadalkareem [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 27.10.2023 published: Electronic UpdateIn: NPJ Vaccines. 2023 Oct 20;8(1):160. - PMID 37863935 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2023.04.17.537235 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356350185 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356350185 | ||
| 003 | DE-627 | ||
| 005 | 20231226070254.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2023.04.17.537235 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1187.xml |
| 035 | |a (DE-627)NLM356350185 | ||
| 035 | |a (NLM)37131704 | ||
| 035 | |a (PII)2023.04.17.537235 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Adam, Awadalkareem |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A single-dose of intranasal vaccination with a live-attenuated SARS-CoV-2 vaccine candidate promotes protective mucosal and systemic immunity |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 27.10.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateIn: NPJ Vaccines. 2023 Oct 20;8(1):160. - PMID 37863935 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a An attenuated SARS-CoV-2 virus with modified viral transcriptional regulatory sequences and deletion of open-reading frames 3, 6, 7 and 8 (∆3678) was previously reported to protect hamsters from SARS-CoV-2 infection and transmission. Here we report that a single-dose intranasal vaccination of ∆3678 protects K18-hACE2 mice from wild-type or variant SARS-CoV-2 challenge. Compared with wild-type virus infection, the ∆3678 vaccination induces equivalent or higher levels of lung and systemic T cell, B cell, IgA, and IgG responses. The results suggest ∆3678 as an attractive mucosal vaccine candidate to boost pulmonary immunity against SARS-CoV-2 | ||
| 650 | 4 | |a Preprint | |
| 700 | 1 | |a Kalveram, Birte |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, John Yun-Chung |e verfasserin |4 aut | |
| 700 | 1 | |a Yeung, Jason |e verfasserin |4 aut | |
| 700 | 1 | |a Rodriguez, Leslie |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Ankita |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Pei-Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Xuping |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Tian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv : the preprint server for biology |d 2020 |g (2023) vom: 18. Apr. |w (DE-627)NLM31090014X |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:18 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2023.04.17.537235 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 18 |c 04 | ||